Elixiron dives into IFNγ and CSF-1R with pathway-centric approach

Our CEO, Hung-Kai Kevin Chen was interviewed by Elise Mak at PharmaDJ about our growth plans and progress towards bringing our clinical-stage assets to patients in need. With a growing cancer immunometabolism pre-clinical pipeline, our two clinical-stage assets so far are an interferon gamma-neutralizing antibody (EI-001) and a CSF1-R kinase inhibitor (EI-1071). EI-001 is being developed for vitiligo, hemophagocytic lymphohistiocytosis and some other as yet undisclosed diseases while EI-1071 is being advanced for the treatment of Alzheimer’s disease and tenosynovial giant cell tumors. Learn more by reading the PharmDJ news report here.